Clearmind Medicine Secures Patent for Novel Addiction Treatment

Author: Evelyn Baker Updated: 03-10-2025 07:30 AM

Clearmind Medicine Announces Innovative Patent Publication

Clearmind Medicine Inc. (Nasdaq: CMND), a pioneering clinical-stage biotech firm, has made significant strides in addressing addiction issues. The company announced the publication of a patent by the Korean Intellectual Property Office for a groundbreaking combination therapy involving MEAI and N-Acylethanolamines aimed at treating cocaine addiction.

Research Foundation for the Patent

This patent stems from compelling preclinical research conducted by Professor Gal Yadid and his team at a prominent brain research center. Their studies demonstrated that MEAI significantly lessened the cravings associated with cocaine in animal models. This discovery is integral in forming a basis for effective therapies combating substance addiction.

Important Findings in Animal Studies

Further investigations into MEAI's effects were conducted to ensure that its impact on drug-seeking behavior did not negatively influence natural rewards, which are crucial for survival. The results were promising: while MEAI successfully reduced cocaine-seeking behavior, it left the animals’ responses to natural rewards unchanged, indicating that its effects are specifically aimed at drug-related compulsions rather than disrupting overall reward systems.

Collaboration with SciSparc Ltd.

Clearmind’s innovative research efforts are part of a broader collaboration with SciSparc Ltd. (NASDAQ: SPRC), which focuses on developing therapies for central nervous system disorders. This partnership allows Clearmind to enhance its MEAI treatment with SciSparc’s PEA, leveraging complementary expertise to develop effective addiction therapies.

Company Overview: Clearmind Medicine Inc.

Founded to address severe and under-treated health issues, Clearmind specializes in developing psychedelic-derived therapeutic compounds. The company is committed to researching these novel treatments and working towards their commercialization as regulated medicines, foods, or supplements.

Intellectual Property Portfolio

Clearmind boasts an impressive intellectual property portfolio consisting of 19 patent families and 31 granted patents. The company remains proactive in seeking additional patents and acquiring new intellectual property to strengthen its position in the market.

Stock Market Presence

Investors can track Clearmind's performance on Nasdaq under the ticker symbol "CMND" and on the Frankfurt Stock Exchange with the symbol “CWY0.” The company’s shares are actively traded, reflecting its growing influence in the biotech sector.

Contact Information

For inquiries or further details regarding Clearmind Medicine and its breakthroughs, interested parties can reach out via:

Investor Relations: invest@clearmindmedicine.com
Telephone: (604) 260-1566

Frequently Asked Questions

What is MEAI?

MEAI is a novel psychedelic treatment being developed for addiction and mental health issues.

How does Clearmind's therapy work?

The therapy aims to reduce cravings for cocaine through the combination of MEAI and N-Acylethanolamines.

What is the significance of the new patent?

The patent validates Clearmind's innovative approach and enhances its competitive edge in developing treatments for addiction.

Who is involved in the research?

The research is led by experts such as Professor Gal Yadid and involves collaborations with SciSparc Ltd.

Where can I find more information about Clearmind Medicine?

More information is available on Clearmind's official website.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.